CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 337 enrolled
Drug / intervention
Lirilumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01714739
NCT01714739Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

Bristol-Myers Squibb·interventional·Posted Oct 26, 2012·Updated Feb 2, 2023

In Brief

A Phase 2 clinical trial evaluating Lirilumab, Nivolumab, and 1 other intervention for CANCER,NOS. Completed, enrolled 337 participants across 30 sites in 6 countries.

Detailed Summary

To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCANCER,NOS
CountriesCanada, France, Italy, Spain, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2012
Enrollment StartOct 7, 2012
Primary CompletionDec 13, 2019
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 13.7 years ago

Interventions

Lirilumabdrug

Specified dose on specified days.

Nivolumabdrug

Specified dose on specified days.

Ipilimumabdrug

Specified dose on specified days.